Figure 3.

RASSF1A was targeted by miR‐330‐3p. A, Heat map: Among 20 microRNAs, miR‐330‐3p was significantly highly expressed in cervical cancer tissues compared with that in adjacent tissues. B, Venn diagram of two sets: Differentially expressed miRNAs and miRNAs targeting RASSF1A. miR‐330‐3p was chosen from nine intersections. C, The estimated RASSF1A binding sites for miR‐330‐3p. D, qRT‐PCR results showed that miR‐330‐3p expression in tumours was significantly higher than that in adjacent tissues. E, RASSF1A expression was negatively correlated with miR‐330‐3p in non‐small‐cell lung cancer (NSCLC) tissues. R = 0.59, P = 0.01. F, qRT‐PCR results showed that miR‐330‐3p expression in NSCLC cell lines was significantly higher than that in normal human lung epithelial cell lines. G, qRT‐PCR results showed that miR‐330‐3p was upregulated by miR‐330‐3p mimics and inhibited by miR‐330‐3p inhibitors. H, RASSF1A was upregulated by miR‐330‐3p mimics and inhibited by miR‐330‐3p inhibitors by qRT‐PCR. I, RASSF1A was upregulated by miR‐330‐3p mimics and inhibited by miR‐330‐3p inhibitors by Western blot. J, The Western blot results in a bar graph. K, miR‐330‐3p decreased the luciferase activity of the RASSF1A wild‐type 3'‐UTR. The data are from one representative experiment among three that were performed identically and are expressed as the means ± SD. **P < 0.01